These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 19156238)

  • 21. Attenuation of the no-reflow phenomenon after coronary angioplasty for acute myocardial infarction with intracoronary papaverine.
    Ishihara M; Sato H; Tateishi H; Kawagoe T; Shimatani Y; Kurisu S; Sakai K
    Am Heart J; 1996 Nov; 132(5):959-63. PubMed ID: 8892767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Dipyridamole versus verapamil for treatment of no-reflow during primary angioplasty.
    Tanzilli G; Greco C; Pasceri V; Pelliccia F; Arrivi A; Placanica A; Mangieri E
    Catheter Cardiovasc Interv; 2010 Nov; 76(6):787-93. PubMed ID: 20737584
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of intracoronary administration of anisodamine on slow reflow phenomenon following primary percutaneous coronary intervention in patients with acute myocardial infarction.
    Fu XH; Fan WZ; Gu XS; Wei YY; Jiang YF; Wu WL; Li SQ; Hao GZ; Wei QM; Xue L
    Chin Med J (Engl); 2007 Jul; 120(14):1226-31. PubMed ID: 17697572
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Treatment of slow/no-reflow phenomenon with intracoronary nitroprusside injection in primary coronary intervention for acute myocardial infarction.
    Wang HJ; Lo PH; Lin JJ; Lee H; Hung JS
    Catheter Cardiovasc Interv; 2004 Oct; 63(2):171-6. PubMed ID: 15390241
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.
    Aung Naing K; Li L; Su Q; Wu T
    Cochrane Database Syst Rev; 2013 Jun; (6):CD009503. PubMed ID: 23736949
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of intracoronary agents on the no-reflow phenomenon during primary percutaneous coronary intervention in patients with ST-elevation myocardial infarction: a network meta-analysis.
    Niu X; Zhang J; Bai M; Peng Y; Sun S; Zhang Z
    BMC Cardiovasc Disord; 2018 Jan; 18(1):3. PubMed ID: 29320987
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of intracoronary anisodamine and diltiazem administration during primary percutaneous coronary intervention in acute myocardial infarction.
    Peng Y; Fu X; Li W; Geng W; Xing K; Ru L; Sun J; Zhao Y
    Coron Artery Dis; 2014 Dec; 25(8):645-52. PubMed ID: 25230304
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Pretreatment with intragraft verapamil prior to percutaneous coronary intervention of saphenous vein graft lesions: results of the randomized, controlled vasodilator prevention on no-reflow (VAPOR) trial.
    Michaels AD; Appleby M; Otten MH; Dauterman K; Ports TA; Chou TM; Gibson CM
    J Invasive Cardiol; 2002 Jun; 14(6):299-302. PubMed ID: 12042618
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of verapamil and adenosine in an adjunct to tirofiban on resolution and prognosis of noreflow phenomenon in patients with acute myocardial infarction.
    Faruk Akturk I; Arif Yalcin A; Biyik I; Sarikamis C; Turhan Caglar N; Erturk M; Celik O; Uzun F; Murat Caglar I; Oner E
    Minerva Cardioangiol; 2014 Oct; 62(5):389-97. PubMed ID: 24699550
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiographic morphologic features of infarct-related arteries and timely reperfusion in acute myocardial infarction: predictors of slow-flow and no-reflow phenomenon.
    Yip HK; Chen MC; Chang HW; Hang CL; Hsieh YK; Fang CY; Wu CJ
    Chest; 2002 Oct; 122(4):1322-32. PubMed ID: 12377860
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intracoronary adenosine administered during aortocoronary vein graft interventions may reduce the incidence of no-reflow phenomenon. A pilot randomised trial.
    Grygier M; Araszkiewicz A; Lesiak M; Grajek S
    Kardiol Pol; 2014; 72(2):126-33. PubMed ID: 23990233
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of intracoronary nitroprusside injection on flow recovery during primary PCI in acute STEMI patients.
    Yang L; Mu L; Sun L; Qi F; Guo R
    Minerva Cardioangiol; 2017 Apr; 65(2):111-118. PubMed ID: 27249789
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Randomized evaluation of intracoronary nitroprusside vs. adenosine after thrombus aspiration during primary percutaneous coronary intervention for the prevention of no-reflow in acute myocardial infarction: the REOPEN-AMI study protocol.
    Niccoli G; D'amario D; Spaziani C; Cosentino N; Marino M; Rigattieri S; Schiavo PL; De Vita MR; Tarantino F; Bartorelli A; Fabbiocchi F; Prati F; Imola F; Valgimigli M; Ferrari R; Crea F
    J Cardiovasc Med (Hagerstown); 2009 Jul; 10(7):585-92. PubMed ID: 19384242
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevention of no flow/slow reflow phenomenon in primary PCI by Nicorandil.
    J E; Juneja MS; George T; Sr R; V V; Ak B; Kalyani S; Pandurangi UM; Latchumanadhas K; S MA
    Indian Heart J; 2007; 59(3):246-9. PubMed ID: 19124934
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of the effects of nitroprusside versus nicorandil on the slow/no-reflow phenomenon during coronary interventions for acute myocardial infarction.
    Kobatake R; Sato T; Fujiwara Y; Sunami H; Yoshioka R; Ikeda T; Saito H; Ujihira T
    Heart Vessels; 2011 Jul; 26(4):379-84. PubMed ID: 21110199
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nicardipine and adenosine "flush cocktail" to prevent no-reflow during rotational atherectomy.
    Fischell TA; Haller S; Pulukurthy S; Virk IS
    Cardiovasc Revasc Med; 2008; 9(4):224-8. PubMed ID: 18928946
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of combined intracoronary adenosine and nicorandil on no-reflow phenomenon during percutaneous coronary intervention.
    Lim SY; Bae EH; Jeong MH; Kang DG; Lee YS; Kim KH; Lee SH; Yoon KH; Hong SN; Park HW; Hong YJ; Kim JH; Kim W; Ahn YK; Cho JG; Park JC; Kang JC
    Circ J; 2004 Oct; 68(10):928-32. PubMed ID: 15459466
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of intracoronary adenosine administration in patients with acute myocardial infarction undergoing primary percutaneous coronary intervention: a meta-analysis of randomized controlled trials.
    Singh M; Shah T; Khosla K; Singh P; Molnar J; Khosla S; Arora R
    Ther Adv Cardiovasc Dis; 2012 Jun; 6(3):101-14. PubMed ID: 22562999
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Randomized trial of intracoronary adenosine as adjunctive therapy for prevention of the no-reflow phenomenon.
    Naghshtabrizi N; Sajedi M; Naghshtabrizi B; Mozayanimonfared A; Ali Seif Rabiei M; Kanonisabet A
    Coron Artery Dis; 2020 Sep; 31(6):527-529. PubMed ID: 32134758
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New method of intracoronary adenosine injection to prevent microvascular reperfusion injury in patients with acute myocardial infarction undergoing percutaneous coronary intervention.
    Grygier M; Araszkiewicz A; Lesiak M; Janus M; Kowal J; Skorupski W; Pyda M; Mitkowski P; Grajek S
    Am J Cardiol; 2011 Apr; 107(8):1131-5. PubMed ID: 21310372
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.